| 单次不同剂量重组人促红细胞生成素治疗肾性贫血的临床研究进展 |
| |
| 引用本文： | 陈存海,宋艳梅. 单次不同剂量重组人促红细胞生成素治疗肾性贫血的临床研究进展[J]. 中华肾病研究电子杂志, 2015, 4(1): 49-51. DOI: 10.3877/cma.j.issn.2095-3216.2015.01.010 |
| |
| 作者姓名： | 陈存海 宋艳梅 |
| |
| 作者单位： | 1. 266000 山东省，青岛市中心医院2. 266000 山东省，青岛市第八人民医院 |
| |
| 摘 要： | 贫血是在慢性肾脏病(CKD)进展过程中最为常见的并发症。红细胞生成素主要是由肾脏产生的一种糖蛋白，用于调节红细胞的生成，它的缺乏是肾性贫血的重要原因。诸多研究显示，对于Hb水平不达标的患者，运用单次大剂量(每次10 000 IU)的重组人促红细胞生成素(rHuEPO)治疗是有效的和安全的。本文就肾性贫血患者的Hb水平现状、不同剂量rHuEPO给药方式的药代动力学特点及相关临床应用及进展予以综述。
|
| 关 键 词： | 肾性贫血 慢性肾脏病 重组人促红细胞生成素 剂量 |
Progress of clinical study on renal anemia treated with single dosage of recombinant human erythropoietin |
| |
| Cunhai Chen,Yanmei Song. Progress of clinical study on renal anemia treated with single dosage of recombinant human erythropoietin[J]. Chinese Journal of kidney disease investigation (Electronic Edition), 2015, 4(1): 49-51. DOI: 10.3877/cma.j.issn.2095-3216.2015.01.010 |
| |
| Authors: | Cunhai Chen Yanmei Song |
| |
| Affiliation: | 1. Central Hospital of Qingdao, Qingdao 266000, China |
| |
| Abstract: | Anemia is the most common complication in the progression of chronic kidney disease (CKD). Erythropoietin is a kind of glycoprotein mainly produced by the kidney, and regulates production of erythrocytes. The lack of erythropoietin is the important reason for renal anemia. Multiple studies showed treatment with a single high dosage (10 000 IU/time) of recombinant human erythropoietin (rHuEPO) is effective and safe in patients with hemoglobin levels lower than the standard. This present paper reviewed the current status of hemoglobin levels in renal anemic patients, pharmacokinetic characteristics of different doses of rHuEPO, and related clinical applications and advancement. |
| |
| Keywords: | Renal anemia Chronic kidney disease Recombinant human erythropoietin Dosage |
| 本文献已被 CNKI 等数据库收录！ |
| 点击此处可从《中华肾病研究电子杂志》浏览原始摘要信息 |
|
点击此处可从《中华肾病研究电子杂志》下载全文 |
